Trial · NCT06505551
Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
NCT06505551, Phase 1, Phase 2, Not yet recruiting, SCG Cell Therapy Pte. Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma. Trials, record NCT06505551. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06505551
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
- NCT number
- NCT06505551
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 66 participants, estimated
- Lead sponsor
- SCG Cell Therapy Pte. Ltd.
- Conditions
HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vaginal Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Head and Neck Cancer
- Interventions
- SCG142, Cyclophosphamide, Fludarabine
- First posted
- 2024-07-17
- Last updated
- 2024-07-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment-Emergent Adverse Events (Phase 1) | 2 years | Incidence of dose-limiting toxicities (DLTs) and occurrence of study related adverse events. |
| Primary | Objective response rate (ORR) (Phase 2) | 2 years | The proportion of patients with a complete response (CR) or partial response (PR) |
| Secondary | Objective response rate (ORR) (Phase 1) | 2 year | The proportion of patients with a complete response (CR) or partial response (PR) |
| Secondary | Duration of objective response (DOR) (Phase 1&2) | 2 year | The time from the first occurrence of a confirmed response to disease progression or death from any cause |
| Secondary | Disease control rate (DCR) (Phase 1&2) | 2 year | The proportion of patients with a CR, PR or stable disease (SD) |
| Secondary | Progression-free survival (PFS) (Phase 1&2) | 2 year | The time from the date of the SCG142 administration to the first occurrence of a progressive disease (PD) or death from any cause |
| Secondary | Overall survival (OS) (Phase 1&2) | 2 year | The time from date of the SCG142 administration to date of death of any cause |
| Secondary | Incidence of Treatment-Emergent Adverse Events (Phase 2) | 2 years | TEAEs |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06505551
GET https://conductscience.org/api/trials/v1/NCT06505551/registered